RAS Mutation Status Should Not Be Used to Predict Outcome from Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases

BACKGROUND: Genetic biomarkers guide systemic anti-cancer treatment (SACT) in metastatic colorectal cancer. It has been suggested they have a role in selecting patients with colorectal peritoneal metastases (CRPM) for cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC)...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhullar, Dilraj, O’Dwyer, Sarah, Wilson, Malcolm, Saunders, Mark P., Kochhar, Rohit, Barriuso, Jorge, Aziz, Omer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Peritoneal Surface Malignancy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807544/
https://www.ncbi.nlm.nih.gov/pubmed/36400886
http://dx.doi.org/10.1245/s10434-022-12704-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807544/
https://www.ncbi.nlm.nih.gov/pubmed/36400886
http://dx.doi.org/10.1245/s10434-022-12704-9

Ejemplares similares